ClinicalTrials.gg
CompletedNCT06177977SS-HH-OCTUpdated Sep 29, 2026

SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)

An interventional study of SS-HH-OCT in Retinal Dystrophies, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 0 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Duke University · Not applicable, Interventional, and Other

How we know

Updated Sep 29, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
137
Allocation
Non-randomized
Ages
0 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Retinal Dystrophies with a site in United States — 8 open to participants now, 16 under way, none of them phase 3. Retinal Dystrophies · United States.

Enrollment
3rd of 16
137 · median 20
Started
2024
with 2 others
No phase
4 of 27
1 open now
Registered
20th of 27
by date
Lead sponsor
1 of 27
Duke University

Among the 27 studies in Retinal Dystrophies with a site in United States, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 with no phase, and was the 20th registered.

Retinal Dystrophies

60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.

Browse Retinal Dystrophies studies →

Open to participants now

8 of the 27 studies in Retinal Dystrophies with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 0 Years to 8 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Retinal Dystrophies with a site in United States, or all of them as a file.
02

Study summary

The goal of this observational study is to utilize a novel imaging system designed for high-resolution retinal imaging of neonates, infants and children to identify the signs of photoreceptor development and degeneration in children with early-onset inherited retinal dystrophies (EORDs). Participants will have research imaging with SS-HH-OCT at the time of clinically-indicated eye examinations or procedures. The investigators aim to establish the basis for utilization of OCT imaging in earlier diagnosis and disease monitoring in children with EORDs. This work will set data reference standards and IRD endpoints that can be used in clinical trials.

Read the detailed description

What photoreceptor degenerative changes take place in children with early-onset inherited retinal dystrophies, and how is photoreceptor development in this patient population affected by genetic defects?

Our novel investigational SS-HH-OCT system features high scanning speed, long laser wavelength, and an ergonomic light-weight handheld design. The investigators hypothesize that imaging with this system will enable us to characterize early-onset retinal dystrophies (EORD)-associated PDCs in young children. To this end, the investigators propose the following specific aims:

Specific Aim 1: Optimize and demonstrate reproducibility of SS-HH-OCT imaging protocols to visualize photoreceptor development and degeneration in children with and without EORDs.

Specific Aim 2: Use SS-HH-OCT parameters to characterize biomarkers of foveal photoreceptor development and degeneration in children with EORDs versus healthy controls.

A total of 80 participants will be enrolled in this study. Participants' age between 0 through 8 years (\<9 years).

For children with EORD, successful completion of this study will result in 1) a framework for reproducible OCT imaging; 2) characterization of biomarkers of retinal degeneration; 3) establishment of reference data by genetic variants 4) insights into foveal development. Additionally, this study will set pilot data of structure-function data and timeline of photoreceptor degeneration for future NIH funded studies.

03

Conditions studied

  • Retinal Dystrophies

Browse trials for

Keywords

  • Retinal dystrophy
  • Inherited retinal dystrophy
  • Early onset retinal dystrophies (EORDS)
04

Who can participate

Ages eligible
0 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all participants:

  • Participant's age is between 0 through 8 years (\<9 years)
  • Parent/legal guardian gives consents for the imaging study
  • No ocular media opacities that could preclude imaging
  • Refractive error equal or lower than 6 diopters

For EORD participants (Groups 1-2):

Meets clinical and molecular diagnosis of EORD (clinical determined by PI). Molecular diagnosis criteria:

  • Autosomal dominant gene: One pathogenic or likely pathogenic variant that meets the clinical phenotype
  • Autosomal recessive gene: two pathogenic or likely pathogenic variants in-trans which meet the phenotype.
  • X-linked gene: one pathogenic or likely pathogenic variant which meets the phenotype.

For Controls (Group 3): No evidence of retinal pathology

Exclusion criteria

Exclusion Criteria:

For all participants:

  • Parent/legal guardian unwilling or unable to provide consent
  • Refractive error higher than 6.00 diopters
  • Participant has media opacities that preclude imaging
  • Any non-IRD ocular condition that confound results interpretation such as glaucoma, uveitis, neurologic conditions affecting the optic nerve, etc.

For EORD participants (Groups 1-2): Does not meet molecular diagnosis criteria

For Controls (Group 3): Any suspicion of IRD

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
137 participants (actual)

Study arms

  • Active comparator
    Group 1 - Progressive Inherited retinal dystrophy (IRD)

    100 participants with progressive IRD; the most common IRD seen at Duke Clinics.

    Device: SS-HH-OCT

  • Active comparator
    Group 2 - Non-progressive Inherited Retinal Dystrophy (IRD)

    20 participants with non-progressive IRD (n=20), a subset of IRDs that are less frequently referred to Duke Clinics

    Device: SS-HH-OCT

  • Active comparator
    Group 3 - Control participants

    50 participants with normal retinal anatomy undergoing anesthesia for strabismus surgery as part of their clinically-indicated care.

    Device: SS-HH-OCT

Interventions

  • DeviceSS-HH-OCT

    The investigational swept source OCT systems with handheld UC handpieces used in this study were developed at Duke University. OCT systems are non-contact, in-vivo optical imaging technology. The OCT system creates real-time, non-invasive images of ocular microstructure. OCT devices held above or in front of the eye while the sweeping infrared OCT beam scans across the retina. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are then stacked to create a volume; the stack may be summed up to create a retinal image. These retinal images are similar to images acquired during retinal photography except that they were captured with infrared light and provide depth information. Each volume and B-scan image can be viewed individually to measure and analyze ocular pathology.

    Also known as: Swept-source Handheld Ultracompact Optical Coherence Tomography (HH UC OCT)

06

What researchers measure

Primary outcomes

  1. Number of participants with abnormal microanatomy as measured by OCT reading

    Presence of abnormal retinal microanatomy as measured by OCT reading

    Time frame: Up to 24 months

  2. Thickness of the participants retina at the fovea and surrounding optic nerve as measured by OCT reading

    Retinal thickness (microns) at the fovea and surrounding optic nerve

    Time frame: Up to 24 months

07

Study locations

1 site
  • Duke University Eye Center
    Durham, North Carolina 27710, United States
08

References and documents

Publications

  • Demas N, Estrada C, Morales P, Jacobs M, Kitchens J, Pearson A, Maldonado R. Inherited retinal diseases in Kentucky: diagnostic yield, gene variants, and novel mutations in a U.S. population. BMC Med Genomics. 2025 Aug 28;18(1):139. doi: 10.1186/s12920-025-02186-5. PubMed 40877827 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2024 to primary completion in Feb 2026, 23 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Dec 2026 → Feb 2026 and completion Dec 2026 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Dec 20, 2023
StartActual
Mar 1, 2024
Primary completionActual
Feb 5, 2026was Dec 2026
CompletionActual
Feb 5, 2026was Dec 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 29, 2026
Primary completion
Dec 2026→Feb 5, 2026 (actual)
Sep 29, 2026
Study completion
Dec 2026→Feb 5, 2026 (actual)
Sep 29, 2026
Enrollment
80 (estimated)→137 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Completed
    Primary completion Dec 2026→Feb 5, 2026 (now actual)
    Study completion Dec 2026→Feb 5, 2026 (now actual)
    Enrollment 80 (estimated)→137 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06177977
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Dec 20, 2023
Start date
Mar 1, 2024
Primary completion
Feb 5, 2026
Completion
Feb 5, 2026
Last update
Sep 29, 2026

Study contacts

Ramiro Maldonado, MD
principal investigator · Duke University Eye Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion